Gainers
- BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
- Global Blood Therapeutics (NASDAQ:GBT) stock increased by 14.94% to $30.91. The market value of their outstanding shares is at $1.9 billion. As per the press release, Q2 earnings came out yesterday.
- Alterity Therapeutics (NASDAQ:ATHE) stock moved upwards by 13.55% to $1.55. The market value of their outstanding shares is at $62.1 million.
- Cerus (NASDAQ:CERS) stock moved upwards by 12.86% to $5.79. The market value of their outstanding shares is at $991.0 million. As per the news, the Q2 earnings report came out yesterday.
- Aquestive Therapeutics (NASDAQ:AQST) shares increased by 10.76% to $3.6. The market value of their outstanding shares is at $131.7 million. The company's, Q2 earnings came out yesterday.
- Aldeyra Therapeutics (NASDAQ:ALDX) shares rose 10.61% to $9.9. The company's market cap stands at $570.5 million.
Losers
- Change Healthcare (NASDAQ:CHNG) shares fell 8.52% to $20.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.2 billion. The company's, Q1 earnings came out today.
- OraSure Technologies (NASDAQ:OSUR) shares declined by 8.22% to $11.39. The company's market cap stands at $819.6 million. As per the press release, Q2 earnings came out yesterday.
- Streamline Health Solns (NASDAQ:STRM) shares fell 8.03% to $1.49. The company's market cap stands at $63.1 million.
- Hancock Jaffe (NASDAQ:HJLI) stock decreased by 6.58% to $6.54. The company's market cap stands at $55.6 million.
- ThermoGenesis Holdings (NASDAQ:THMO) stock declined by 6.48% to $2.31. The market value of their outstanding shares is at $27.5 million.
- Clovis Oncology (NASDAQ:CLVS) stock decreased by 6.38% to $4.55. The market value of their outstanding shares is at $475.7 million. As per the news, the Q2 earnings report came out today.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.